Biotech company CavoGene LifeSciences has licensed a novel investigational gene therapy from the University of California San Diego and brought the technology across the country to Cleveland, where the six-month-old firm will be headquartered.
The move — facilitated by Cleveland’s health care and bioscience business accelerator, BioEnterprise — comes as the regenerative medicine industry is seeing a surge in investment, promising clinical trials and strong partnering opportunities.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutré.
Originally published February 10, 2019.